摘要: Cancer-related anaemia has a number of causes, not least the underlying malignancy itself which plays role in suppressing erythropoiesis. Anaemia is often exacerbated by cancer treatments, particular routinely used cytotoxic chemotherapy. Chronic characterized inappropriately low levels endogenous erythropoietin for degree anaemia, and manifests clinically with generalized hypoxia resultant severe fatigue. Epoetin alfa one recombinant form erythropoietin, primary human growth factor responsible promoting proliferation survival erythroid progenitor cells. been widely studied treatment associated renal failure now recognized as having significant potential management cancer-related anaemia. Studies suggest that epoetin an effective proportion patients symptomatic It also appears useful prevention chemotherapy-induced different settings have shown significantly increases haemoglobin haematocrit, reduces transfusion requirements improves quality life patient.
oup.com
paperity.org参考文章(13)
Abels Ri, Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Seminars in Oncology. ,vol. 19, pp. 29- 35 ,(1992)
H Ludwig, E Fritz, Anemia of cancer patients : Patient selection and patient stratification for epoetin treatment Seminars in Oncology. ,vol. 25, pp. 35- 38 ,(1998)
D. H. Henry, Epoetin alfa and high-dose chemotherapy. Seminars in Oncology. ,vol. 25, pp. 54- 57 ,(1998)
J Glaspy, R Bukowski, D Steinberg, C Taylor, S Tchekmedyian, S Vadhan-Raj, Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. Journal of Clinical Oncology. ,vol. 15, pp. 1218- 1234 ,(1997) , 10.1200/JCO.1997.15.3.1218
I. C. Macdougall, M. E. Davies, R. D. Hutton, I. Cavill, N. P. Lewis, G. A. Coles, J. D. Williams, The Treatment of Renal Anaemia in CAPD Patients with Recombinant Human Erythropoietin Nephrology Dialysis Transplantation. ,vol. 5, pp. 950- 955 ,(1990) , 10.1093/NDT/5.11.950
J.R. Skillings, I. Rogers-Melamed, J.-M. Nabholtz, C. Sawka, F. Gwadry-Sridhar, J.-P. Moquin, M. Rubinger, P. Ganguly, M. Burnell, C. Shustik, D. Dryer, M. McLaughlin, D. White, W. Mertens, 879 An epidemiological review of anaemia in cancer chemotherapy in Canada European Journal of Cancer. ,vol. 31, pp. S183- ,(1995) , 10.1016/0959-8049(95)96128-Z
G. Vreugdenhil, B. Manger, C. Nieuwenhuizen, R. A. Feelders, H. G. van Eijk, A. J. G. Swaak, Iron stores and serum transferrin receptor levels during recombinant human erythropoietin treatment of anemia in rheumatoid arthritis. Annals of Hematology. ,vol. 65, pp. 265- 268 ,(1992) , 10.1007/BF01836071
Stanley Dische, Radiotherapy and anaemia — the clinical experience Radiotherapy and Oncology. ,vol. 20, pp. 35- 40 ,(1991) , 10.1016/0167-8140(91)90184-I
Clemens Leitgeb, Martin Pecherstorfer, Elke Fritz, Heinz Ludwig, Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer. ,vol. 73, pp. 2535- 2542 ,(1994) , 10.1002/1097-0142(19940515)73:10<2535::AID-CNCR2820731014>3.0.CO;2-5
Yves Beguin, Prediction of response to optimize outcome of treatment with erythropoietin. Seminars in Oncology. ,vol. 25, pp. 27- 34 ,(1998)